Association of thromboelastography profile with severity of liver cirrhosis and portal venous system thrombosis

Yanglan He1,3†, Shanshan Yuan2†, Xiaozhong Guo1†, Fangfang Yi1†, Xiangbo Xu1, Yang An1, Shixue Xu1,3, Walter Ageno4 and Xingshun Qi1*

Abstract
Background and aim: Hemostasis profile is often complicated in liver cirrhosis. Thromboelastography is a global viscoelastic test recommended by the current practice guideline and consensus. This cross-sectional study aimed to evaluate the association of thromboelastography profile with severity of liver cirrhosis and presence of portal venous system thrombosis (PVST).

Methods: Overall, 116 and 50 cirrhotic patients were included in the Shenyang and Xi’an cohorts, respectively. Thromboelastography parameters were compared between cirrhotic patients with Child–Pugh class A and B/C, those with and without decompensated events, and those with and without PVST. Hypercoagulability would be considered if at least two of the following thromboelastography parameters were met: shortened reactive time (R), shortened coagulation time (K), increased angle, and increased maximum amplitude (MA).

Results: In the Shenyang cohort, 16 patients had shortened R, of whom seven (43.75%) had prolonged K and 11 (68.75%) decreased MA. In the Xi’an cohort, 24 patients had shortened R, of whom seven (29.17%) had prolonged K and 15 (62.50%) decreased MA. In the Shenyang cohort, the prevalence of hypercoagulability was not significantly different between cirrhotic patients with Child–Pugh class A and B/C (3.85% vs. 6.25%, P = 0.873), those with and without decompensated events (5.49% vs. 4.00%, P = 1.000), and those with and without PVST (4.17% vs. 5.88%, P = 1.000), which were similar to the results obtained in the Xi’an cohort.

Conclusion: There is a high rate of discordance between R and other thromboelastography parameters. In addition, hypercoagulability may not be related to more advanced stage of liver cirrhosis or presence of PVST.

Keywords: Thromboelastography, Hepatic, Cirrhosis, Thrombosis, Hypercoagulability

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
cirrhosis [2, 4, 5]. By comparison, thromboelastography (TEG) is a novel global viscoelastic test, and the current guidelines and consensus have stated that TEG can evaluate the status of hemostasis more comprehensively [6, 7].

In this study, we aimed to describe the hemostasis status by TEG in cirrhotic patients and to explore the correlation of hemostatic changes with the severity of liver cirrhosis and presence of portal venous system thrombosis (PVST).

Methods

Population selection
This retrospective study included two cohorts (i.e., “Shenyang cohort” and “Xi’an cohort”). All adult patients with cirrhosis who were consecutively admitted to the Department of Gastroenterology of the General Hospital of Northern Theater Command and the Department of Gastroenterology of the Xi’an Central Hospital from July 1, 2018 to September 30, 2020 and underwent TEG test during their hospitalizations were potentially eligible for the study. Exclusion criteria were as follows: (1) a highly suspected or definite diagnosis of malignancy; (2) a known history of primary coagulopathy; (3) active infection at the time of TEG test; (4) a history of abdominal surgery [8], such as splenectomy [9], liver transplantation, transjugular intrahepatic portosystemic shunt, appendectomy, and cholecystectomy; (5) patients who received drugs with documented impact on coagulation status within 4 weeks prior to the TEG test; (6) a history of blood transfusion within 2 weeks prior to the TEG test; and (7) missing data of TEG test.

Assessment of hemostasis status
CCTs mainly include PT, PLT, and fibrinogen (FIB). PT is used for evaluating the integrity of both extrinsic and common pathways of coagulation [10]. PLT and fibrinogen are used for evaluating the defects of the primary and secondary hemostasis.

TEG, a viscoelastic test, evaluates the global hemostasis state, mainly including the initiation of fibrin formation, rate of clot development, and maximum clot strength [11] (Additional file 1: Table S1). The TEG profile in the Shenyang cohort was assessed by the Thrombelastograph 5000 system (Haemoscope Corporation, USA), while the TEG profile in the Xi’an cohort was detected by the CFMSLEPU-8800 (Lepu Technology, China). In both Shenyang and Xi’an cohorts, the whole blood sample activated by citrated kaolin was added into a cup where the temperature remained 37 degrees Centigrade. A pin was placed in the sample when the cup was rotating. The sensor attached on the cup began to detect the viscoelastic changes of the sample once coagulation process was initiated. The TEG parameters mainly included reactive time (R), coagulation time (K), angle (α), maximum amplitude (MA). The hypercoagulability and hypocoagulability indicated by TEG parameters are shown in Additional file 1: Table S1.

Diagnosis
A diagnosis of liver cirrhosis was mainly based on clinical, laboratory, and radiological examinations, and/or histological data, if necessary. Decompensated events included ascites, gastrointestinal bleeding, hepatic encephalopathy, and acute-on-chronic liver failure. The severity of liver cirrhosis was evaluated by Child–Pugh score. PVST was diagnosed according to the findings of contrast-enhanced computed tomography (CT)/magnetic resonance imaging (MRI) scans. PVST refers to thrombosis within portal vein trunk, intrahepatic portal vein, splenic vein, or mesenteric vein.

Hypercoagulability would be considered, if at least two of the following criteria were met: shortened R, shortened K, increased α, or increased MA as compared to the reference range.

Statistical analysis
Qualitative data were described as frequency (percentage) and compared by χ² or Fisher’s exact tests. Quantitative data were described by median (range) and compared by Mann–Whitney U test. The correlation between quantitative data was assessed by Spearman’s test. Statistical significance was defined as a P < 0.05. All the statistical data were calculated by IBM SPSS 22.0 (IBM Corp, Armonk, NY, USA). The violin plots demonstrating the distribution of CCTs and TEG and the scatter diagrams of R and other TEG parameters were drawn by the GraphPad Prism version 8.0 (GraphPad Software, Inc., La Jolla, California, USA).

Results

Patient characteristics
In the Shenyang cohort, 159 patients with cirrhosis underwent TEG test. Among them, 43 patients were excluded, 15 with definite or highly suspected diagnosis of malignancy, 2 with active infection, 16 with a history of abdominal surgery, 7 treated with drugs influencing coagulation status, 1 treated with fresh frozen plasma transfusion, and 2 with missing data. Finally, 116 patients were included, of whom 94 (81.03%) and 101 (87.06%) patients had abnormal PT and PLT, respectively (Fig. 1).

In the Xi’an cohort, 112 patients with cirrhosis underwent TEG test. Among them, 62 patients were excluded, 2 with definite or highly suspected diagnosis of malignancy, 3 with active infection, 34 with a history of abdominal surgery, 16 treated with drugs influencing...
Finally, 50 patients were included, of whom 34 (69.39%) and 38 (76.00%) patients had abnormal PT and PLT, respectively (Additional file 2: Fig. S1).

**TEG profile**

In the Shenyang cohort, 21 (18.10%), 59 (50.86%), 31 (26.72%), and 77 (66.38%) patients had abnormal R, K, α, and MA, respectively (Fig. 1). Sixteen (13.79%), four (3.45%), 23 (19.83%), and 0 (0%) patients had shortened R, shortened K, increased α, and increased MA as compared to the reference range, respectively. Among the 16 patients with shortened R, two (12.50%) had shortened K, four (25.00%) had increased α, and 0 (0.00%) had increased MA; by contrast, seven (43.75%) had prolonged K, 0 (0.00%) had decreased α, and 11 (68.75%) had decreased MA (Fig. 2). Six (5.17%) patients had hypercoagulability defined by TEG profile.

In the Xi’an cohort, 24 (48.00%), 21 (42.00%), eight (16.00%), and 34 (68.00%) patients had abnormal R, K, α, and MA, respectively (Additional file 2: Fig. S1). Twenty-four (48.00%), three (6.00%), six (12.00%), and two (4.00%) patients had shortened R, shortened K, increased α, and increased MA as compared to the reference range, respectively. Among the 24 patients with shortened R, three (12.50%) had shortened K, six (25.00%) had increased α, and two (8.33%) had increased MA; by contrast, seven (29.17%) had prolonged K, 0 (0.00%) had decreased α, and 15 (62.50%) had decreased MA (Additional file 3: Fig. S2). Six (12.00%) patients had hypercoagulability defined by TEG profile.

---

**Fig. 1** CCTs and TEG parameters in the Shenyang cohort. Notes Grey area represents the reference range of PT, PLT, and TEG parameters. N represents the number of patients undergoing PT, PLT, and TEG test.
Comparison between Child–Pugh class A and Child–Pugh class B/C cirrhosis

In the Shenyang cohort, there were 52 Child–Pugh class A and 64 Child–Pugh class B/C cirrhotic patients (Table 1). Compared to Child–Pugh class A cirrhotic patients, Child–Pugh class B/C cirrhotic patients had non-significantly shorter R, longer K, larger α, and lower MA. The proportions of hypocoagulability indicated by prolonged R, prolonged K, decreased α, and decreased MA were not significantly different between the two groups. The proportions of hypercoagulability indicated by shortened R, shortened K, increased α, and increased MA were not significantly different between them. The prevalence of hypercoagulability defined by TEG profile was not significantly different between the two groups (3.85% vs. 6.25%, \( P = 0.873 \)).

In the Xi'an cohort, there were 15 Child–Pugh class A and 35 Child–Pugh class B/C cirrhotic patients (Additional file 4: Table S2). Compared to Child–Pugh class A cirrhotic patients, Child–Pugh class B/C cirrhotic patients had significantly lower MA, and non-significantly shorter R, longer K, and smaller α. The proportions of hypocoagulability indicated by prolonged R, prolonged K, decreased α, and decreased MA were not significantly different between the two groups. The proportions of hypercoagulability indicated by shortened R, shortened K, increased α, and increased MA were not significantly different between them. The prevalence of hypercoagulability defined by TEG profile was not significantly different between the two groups (6.67% vs. 14.29%, \( P = 0.776 \)).

Comparison between cirrhosis with and without decompensated events

In the Shenyang cohort, there were 91 and 25 cirrhotic patients with and without decompensated events, respectively (Table 2). Compared to those without, cirrhotic patients with decompensated events had significantly shorter R, and non-significantly shorter K, larger α, and lower MA. The proportions of hypocoagulability indicated by prolonged R, prolonged K, decreased α, and decreased MA were not significantly different between the two groups. The proportions of hypercoagulability indicated by shortened R, shortened K, increased α, and increased MA were not significantly different between them. The prevalence of hypercoagulability defined by TEG profile was not significantly different between the two groups (6.67% vs. 14.29%, \( P = 0.776 \)).

In the Xi'an cohort, there were 39 and 11 cirrhotic patients with and without decompensated events, respectively (Additional file 5: Table S3). Compared to those without, cirrhotic patients with decompensated events had significantly shorter R, longer K, and

---

**Table 1** Difference of TEG profile between Child–Pugh class A and B/C cirrhosis in the Shenyang cohort

| Variables | Child–Pugh class A | Child–Pugh class B/C | \( P \) value |
|-----------|---------------------|----------------------|--------------|
|           | Median (range) or frequency | Median (range) or frequency |              |
| TEG profile |                      |                      |              |
| R (min)   | 6.80 (3.80–11.80) | 6.20 (3.20–13.80) | 0.119        |
| Prolonged R | 2/52 (3.85) | 3/64 (4.69) | 1.000        |
| Shortened R | 4/52 (7.69) | 12/64 (18.75) | 0.108        |
| K (min)   | 2.90 (0.90–6.50) | 2.95 (0.80–9.20) | 0.923        |
| Prolonged K | 24/52 (46.15) | 31/64 (48.44) | 0.853        |
| Shortened K | 1/52 (1.92) | 3/64 (4.69) | 0.627        |
| α (°)     | 64.15 (48.20–79.60) | 65.80 (49.50–80.70) | 0.355       |
| Decreased α | 4/52 (7.69) | 4/64 (6.25) | 1.000        |
| Increased α | 9/52 (17.31) | 14/64 (21.88) | 0.642        |
| MA (mm)   | 47.15 (32.70–65.50) | 45.00 (28.60–68.40) | 0.445       |
| Decreased MA | 32/52 (61.54) | 45/64 (70.31) | 0.332        |
| Increased MA | 0/52 (0) | 0/64 (0) | –            |
| Hypercoagulability | 2/52 (3.85) | 4/64 (6.25) | 0.873        |

R: Reaction time; K: Coagulation time; α: Angel; MA: Maximum Amplitude; min: minutes; °: degrees; mm: millimeters
The proportions of hypocoagulability indicated by prolonged R, prolonged K, decreased α, and decreased MA were not significantly different between the two groups. Compared to those without, cirrhotic patients with decompen-sated events had a significantly higher proportion of hypercoagulability indicated by shortened R, but the proportions of hypercoagulability indicated by shortened K, increased α, and increased MA were not significantly different between the two groups. The prevalence of hypercoagulability defined by TEG profile was not significantly different between the two groups (0% vs. 15.38%, P = 0.317).

### Comparison between cirrhotic patients with and without PVST

In the Shenyang cohort, 75 patients underwent contrast-enhanced CT or MRI, of whom 24 had PVST and 51 did not have PVST (Table 3). PVST was asymptomatic in all of 24 patients. Compared to those without, cirrhotic patients with PVST had significantly lower MA, and non-significantly shorter R, longer K, and smaller α. The

### Table 2: Difference of TEG profile between cirrhosis with and without decompensated events in the Shenyang cohort

| Variables | Cirrhosis without decompensated events | Cirrhosis with decompensated events | P value |
|-----------|----------------------------------------|-------------------------------------|---------|
| R (min)   | Median (range or frequency (percentage)) | Median (range or frequency (percentage)) |         |
| Prolonged R | 7.10 (3.80–11.80) | 6.20 (3.20–13.80) | 0.017   |
| Shortened R | 1/25 (4.00) | 4/91 (4.40) | 1.000   |
| K (min)  | 3.00 (0.90–7.40) | 2.90 (0.80–9.20) | 0.882   |
| Prolonged K | 11/25 (44.00) | 44/91 (48.35) | 0.822   |
| Shortened K | 1/25 (4.00) | 3/91 (3.30) | 1.000   |
| α (°)   | 64.20 (48.20–79.60) | 65.50 (49.60–80.70) | 0.539   |
| Decreased α | 4/25 (16.00) | 4/91 (4.40) | 0.065   |
| Increased α | 6/25 (24.00) | 17/91 (18.68) | 0.576   |
| MA (mm)  | 49.40 (33.90–65.50) | 45.50 (28.60–68.40) | 0.452   |
| Decreased MA | 14/25 (56.00) | 63/91 (69.23) | 0.238   |
| Increased MA | 0/25 (0) | 0/91 (0) | –       |

### Table 3: Difference of TEG profile between cirrhosis with and without PVST in the Shenyang cohort

| Variables | Cirrhosis without PVST | Cirrhosis with PVST | P value |
|-----------|-------------------------|---------------------|---------|
| R (min)   | Median (range or frequency (percentage)) | Median (range or frequency (percentage)) |         |
| Prolonged R | 6.80 (3.50–13.70) | 6.30 (4.20–11.20) | 0.436   |
| Shortened R | 2/51 (3.92) | 1/24 (4.17) | 1.000   |
| K (min)  | 2.80 (0.80–7.90) | 3.60 (1.20–6.30) | 0.064   |
| Prolonged K | 20/51 (39.22) | 15/24 (62.50) | 0.083   |
| Shortened K | 2/51 (3.92) | 0/24 (0) | 0.559   |
| α (°)   | 65.90 (50.10–80.70) | 63.55 (48.20–76.40) | 0.121   |
| Decreased α | 4/51 (7.84) | 1/24 (4.17) | 0.667   |
| Increased α | 11/51 (21.57) | 3/24 (12.50) | 0.527   |
| MA (mm)  | 48.50 (30.60–68.40) | 43.75 (37.20–60.20) | 0.014   |
| Decreased MA | 31/51 (60.78) | 20/24 (83.33) | 0.065   |
| Increased MA | 0/51 (0) | 0/24 (0) | –       |

Hypercoagulability | 1/25 (4.00) | 5/91 (5.49) | 1.000   |
proportions of hypocoagulability indicated by prolonged R, prolonged K, decreased α, and decreased MA were not significantly different between the two groups. The proportions of hypercoagulability indicated by shortened R, shortened K, increased α, and increased MA were not significantly different between the two groups. The prevalence of hypercoagulability defined by TEG profile was not significantly different between the two groups (5.88% vs. 4.17%, P = 1.000).

In the Xi’an cohort, 48 patients underwent contrast-enhanced CT or MRI, of whom 10 had PVST and 38 did not have PVST (Additional file 6: Table S4). PVST was asymptomatic in all of 10 patients. Compared to those without, cirrhotic patients with PVST had non-significantly shorter R, longer K, smaller α, and lower MA. Compared to those without, the cirrhotic patients with PVST had significantly higher proportion of hypercoagulability indicated by decreased α, but the proportions of hypocoagulability indicated by prolonged R, prolonged K, and decreased MA were not significantly different between the two groups. The proportions of hypercoagulability indicated by shortened R, shortened K, increased α, and increased MA were not significantly different between them. The prevalence of hypercoagulability defined by TEG profile was not significantly different between the two groups (13.16% vs. 0.00%, P = 0.569).

Correlation between TEG and CCTs in cirrhosis
The correlation between TEG parameters and CCTs in cirrhosis is shown in Additional file 7: Table S5. In both Shenyang and Xi’an cohorts, K, α, and MA, but not R, significantly correlated with CCTs.

Discussion
Patients with cirrhosis are often considered to be at risk for bleeding because of deteriorated or abnormal CCTs. Recent evidence demonstrated that elevated INR was not indicative of a higher risk for bleeding [12–14], as in such patients, the hemostatic status assessed by thrombin generation assays was rather normal [2, 4, 5] due to a simultaneous deficiency of both pro- and anti-coagulants [15]. Accordingly, current guideline and consensus do not recommend the use of conventional coagulation parameters for the assessment of coagulation status and bleeding risk in liver cirrhosis [6]. TEG can provide comprehensive information about function and amounts of pro-coagulants, anti-coagulants, and PLT as well as their interactions [16, 17]. In cirrhotic patients, TEG often shows normal global hemostasis, in spite of abnormal CCTs [18, 19]. Similarly, in our study, abnormal hemostatic status indicated by CCTs was more common than those indicated by TEG in both Shenyang and Xi’an cohorts.

In accordance with previous studies [17, 20], our current study showed a trend towards hypocoagulability, indicated by most of the TEG parameters, in patients with more advanced liver cirrhosis. However, it should be noted that R is often discordant with other TEG parameters. Both Shenyang and Xi’an cohorts demonstrated a lower MA, indicating the presence of hypocoagulability, in patients with decompensated events than those without; contrarily, a significantly shorter R, indicating the presence of hypercoagulability, in patients with decompensated events than those without. Such an opposite correlation is also observed among our individuals with shorter R but lower MA. This unexpected phenomenon could be explained by the fact that PLT and FIB were not closely associated with R [17, 21], but with K, α, and MA [17, 20]. Therefore, we could not arbitrarily define hypercoagulability by shortened R alone. Furthermore, our current study employed a new definition of hypercoagulability, which was different from previous study [17]. In details, in our study, hypercoagulability was diagnosed based on at least two of the following four TEG parameters: shortened R, shortened K, increased α, and increased MA. According to the diagnostic criteria, our study suggested that more advanced cirrhosis might not have a higher probability of hypercoagulability than less advanced cirrhosis.

A previous study by Zanetto et al. found that hypercoagulation indicated by higher MA was associated with PVST in cirrhotic patients with hepatocellular carcinoma [22]. Given that cancer itself could also trigger hypercoagulation, we could not extrapolate the association between TEG profile and PVST in non-malignant liver cirrhosis from the Zanetto’s findings. Huang et al. found a significantly shorter R in cirrhotic patients with non-tumoral PVST as compared to those without [23]. Notably, Huang et al. included only patients with gastroesophageal varices but we also included patients with other complications of liver cirrhosis. Though we had a large number of patients with shortened R, we did not find any significant difference in median R and proportion of shortened R between cirrhotic patients with and without PVST. Thus, our findings also suggested that hypercoagulability indicated by TEG profile might not be an important contributor to PVST formation in cirrhosis. This finding is similar to the findings of our previous meta-analysis that antithrombin, protein C, and protein S levels were not significantly different between patients with and without PVST after matching Child–Pugh class [24]. It has been widely recognized that the formation of PVST may be multifactorial in liver cirrhosis [25, 26]. After adjusting other thrombotic risk factors, such as antithrombin, protein C, lupus anticoagulant, cryoglobulins, and hyper-homocysteine, decreased portal
vein velocity might be the most important risk factor for PVST formation [27].

Our study employed two cohorts to analyze TEG profile in liver cirrhosis, and the results in the Shenyang cohort were generally similar to those in the Xi’an cohort. However, there were several limitations in our study. First, TEG facilities and reference ranges are different at the two centers, in spite of the same reagents (citrated kaolin) and technical principles. Second, the characteristics of included patients were not the same between the two centers, which might contribute to the heterogeneity of TEG values obtained from the two cohorts. Third, our cirrhotic patients have asymptomatic PVST without acute abdomen. Thus, the correlation of TEG profile with the age of PVST could not be evaluated. Forth, we did not measure levels of coagulation factors to evaluate the association of shortened R with coagulation factors.

**Conclusion**

TEG profile suggests a relatively normal hemostasis status in liver cirrhosis. However, there is a high rate of discordance between R and other TEG parameters. Hypercoagulability indicated by TEG parameters may not be related to more advanced stage of liver cirrhosis. Additionally, systemic hypercoagulability detected by TEG profile may not be a major contributor of PVST in liver cirrhosis.

**Abbreviations**

α: Angle; CCTs: Conventional coagulation tests; CT: Computed tomography; INR: International normalized ratio; K: Coagulation time; MA: Maximum amplitude; MRI: Magnetic resonance imaging; PLT: Platelet; PT: Prothrombin time; PVST: Portal venous system thrombosis; R: Reactive time; TEG: Thromboelastography.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12876-021-01832-3.

**Acknowledgements**

We would like to appreciate our study team for setting up and updating the prospective database, including Wenchun Bao, Feifei Hou, Zeqi Guo, Jingqiao Zhang, Xinmiao Zhou, Miaomiao Li, Ruirui Feng, Cen Hong, and Shixue Xu, of whom all had worked for our study group of establishing and updating this database, which prospectively recorded the patients treated by Dr. Xingshun Qi.

The abstract was published in the Asian Pacific Association for the Study of the Liver (APASL) 2020 Conference as a poster presentation. Please see the following link: https://link.springer.com/content/pdf/10.1007/s12072-020-10030-4.pdf.

**Authors’ contributions**

YH and XQ were involved in the concept and design of study; YH, SY, FY, and XQ were involved in the data curation; YH, XX, YA, SX, and XQ were involved in statistical analysis; YH, SY, and XQ were involved in drafting the manuscript; all authors were involved in writing—review and editing; XG and XQ were involved in the supervision of study. All authors have made an intellectual contribution to the manuscript and approved the submission. All authors read and approved the final manuscript.

**Funding**

The study was partially supported by the Science and Technology Project Foundation of Shenyang (19-112-4-005) and Science and Technology Project Foundation of Liaoning (2020.H2/10300163).

**Availability of data and materials**

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This study was conducted in accordance with the Declaration of Helsinki and was reviewed and approved by the Medical Ethical Committee of General Hospital of Northern Theater Command. Written informed consent was waived by Medical Ethical Committee of General Hospital of Northern Theater Command. The approval number was Y (2021) 016.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), No. 83 Wenhuia Road, Shenyang 110840, Liaoning Province, China. 2. Department of Gastroenterology, Xi’an Central Hospital, Xi’an 710003, China. 3. Postgraduate College, China Medical University, Shenyang 110122, China. 4. Department of Medicine and Surgery, University of Insubria, Varese, Italy.

**Received:** 18 February 2021  **Accepted:** 25 May 2021  **Published online:** 07 June 2021
References

1. Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20:5442–60.

2. Kujovich JL. Coagulopathy in liver disease: a balancing act. Hematology. 2015;2015:243–9.

3. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis. 2002;22:83–96.

4. Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006;44:1039–46.

5. Tripodi A. Hemostasis abnormalities in cirrhosis. Curr Opin Hematol. 2015;22:406–12.

6. O’Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: coagulation in cirrhosis. Gastroenterology. 2019;157:34-43.e31.

7. Lippi G, Favaloro EJ, Franchini M. Dangers in the practice of defen-sive medicine in hemostasis testing for investigation of bleeding or thrombosis: part I—routine coagulation testing. Semin Thromb Hemost. 2014;40:812–24.

8. Zhang B, Kim M, Griffiths C, et al. Incidence of splanchnic vein thrombosis after abdominal surgery: a systematic review and meta-analysis. J Surg Res. 2020;245:500–9.

9. Wu Y, Li H, Zhang T, et al. Splanchnic vein thrombosis in liver cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41:553–8.

10. Reikvam H, Steien E, Hauge B, et al. Thromboelastography. Transfus Apher Sci. 2009;40:119–23.

11. Shin KH, Kim IS, Lee HJ, et al. Thromboelastographic evaluation of coagulation in patients with liver disease. Ann Lab Med. 2017;37:204–12.

12. Stravitz RT. Potential applications of thromboelastography in patients with acute and chronic liver disease. Gastroenterol Hepatol. 2017;8:513–20.

13. Somani V, Amarapurkar D, Shah A. Thromboelastography for assessing the risk of bleeding in patients with cirrhosis-moving closer. J Clin Exp Hepatol. 2017;7:284–9.

14. Kohli R, Shingina A, New S, et al. Thromboelastography parameters are associated with cirrhosis severity. Dig Dis Sci. 2019;64:2661–70.

15. Tripodi A, Primignani M, Chantarangkul V, et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res. 2009;124:132–6.

16. Zanetto A, Senzolo M, Viale A, et al. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig and Liver Dis. 2017;49:440–5.

17. Huang X, Fan X, Zhang R, et al. Systemic inflammation and portal vein thrombosis in cirrhotic patients with gastrointestinal varices. Eur J Gastroenterol Hepatol. 2019;32:401–5.

18. Qi X, Chen H, Han G. Effect of antithrombin, protein C and protein S on portal vein thrombosis in liver cirrhosis: a meta-analysis. Am J Med Sci. 2013;346:38–44.

19. Harding DJ, Perera MT, Chen F, et al. Portal vein thrombosis in cirrhosis: controversies and latest developments. World J Gastroenterol. 2015;21:6769–84.

20. Qi X, Li H, Liu X, et al. Novel insights into the development of portal vein thrombosis in cirrhosis patients. Expert Rev Gastroenterol Hepatol. 2015;9:1421–32.

21. Zoccola MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009;51:682–9.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.